Literature DB >> 24365877

Application of single-vial ready-for-use formulation of 111In- or 177Lu-labelled somatostatin analogs.

Erik de Blois1, Ho Sze Chan1, Rory de Zanger1, Mark Konijnenberg1, Wouter A P Breeman2.   

Abstract

For the sake of safety it would be desirable to store and transport the ready-for-use liquid formulation (diagnostics and therapeutics) of radiolabelled peptides. The use of ethanol, in combination with a mixture of gentisic- and ascorbic acid, has superior effects on stabilizing radiolabelled somatostatin analogs. As a consequence, (111)In- and (177)Lu-labelled somatostatin analogs can be stored and transported in a single-vial ready-for-use liquid formulation up to 7 days after radiolabelling.
© 2013 Published by Elsevier Ltd.

Entities:  

Keywords:  Ascorbic acid; Ethanol; Gentisic acid; Quenchers; Radiochemical purity; Somatostatin

Mesh：

Substances：

Year:  2013        PMID： 24365877     DOI： 10.1016/j.apradiso.2013.10.023

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN： 0969-8043            Impact factor:   1.513


  9 in total

1.  Comparative Effects of Metal-Catalyzed Oxidizing Systems on Carbonylation and Integrity of Therapeutic Proteins.

Authors:  Dmitry Kryndushkin; V Ashutosh Rao
Journal:  Pharm Res       Date:  2015-10-23       Impact factor: 4.200

2.  177Lu-Labeled Phosphoramidate-Based PSMA Inhibitors: The Effect of an Albumin Binder on Biodistribution and Therapeutic Efficacy in Prostate Tumor-Bearing Mice.

Authors:  Cindy J Choy; Xiaoxi Ling; Jonathan J Geruntho; Sophia K Beyer; Joseph D Latoche; Beatrice Langton-Webster; Carolyn J Anderson; Clifford E Berkman
Journal:  Theranostics       Date:  2017-04-27       Impact factor: 11.556

3.  Inter and intra-tumor somatostatin receptor 2 heterogeneity influences peptide receptor radionuclide therapy response.

Authors:  Danny Feijtel; Gabriela N Doeswijk; Nicole S Verkaik; Joost C Haeck; Daniela Chicco; Carmelina Angotti; Mark W Konijnenberg; Marion de Jong; Julie Nonnekens
Journal:  Theranostics       Date:  2021-01-01       Impact factor: 11.556

4.  Autoradiographical assessment of inflammation-targeting radioligands for atherosclerosis imaging: potential for plaque phenotype identification.

Authors:  Eric J Meester; Erik de Blois; Boudewijn J Krenning; Antonius F W van der Steen; Jeff P Norenberg; Kim van Gaalen; Monique R Bernsen; Marion de Jong; Kim van der Heiden
Journal:  EJNMMI Res       Date:  2021-03-17       Impact factor: 3.138

5.  Development of [225Ac]Ac-PSMA-I&T for Targeted Alpha Therapy According to GMP Guidelines for Treatment of mCRPC.

Authors:  Eline L Hooijman; Yozlem Chalashkan; Sui Wai Ling; Figen F Kahyargil; Marcel Segbers; Frank Bruchertseifer; Alfred Morgenstern; Yann Seimbille; Stijn L W Koolen; Tessa Brabander; Erik de Blois
Journal:  Pharmaceutics       Date:  2021-05-13       Impact factor: 6.321

6.  Radiochemical and analytical aspects of inter-institutional quality control measurements on radiopharmaceuticals.

Authors:  Erik de Blois; Rory M S de Zanger; Ho Sze Chan; Mark Konijnenberg; Wouter A P Breeman
Journal:  EJNMMI Radiopharm Chem       Date:  2019-01-28

7.  Oxidant and Antioxidant Effects of Gentisic Acid in a <sup>177</sup>Lu-Labelled Methionine-Containing Minigastrin Analogue.

Authors:  Victoria Trindade; Henia Balter
Journal:  Curr Radiopharm       Date:  2020

8.  Imaging inflammation in atherosclerotic plaques, targeting SST2 with [111In]In-DOTA-JR11.

Authors:  Monique R Bernsen; Kim van der Heiden; Eric J Meester; Boudewijn J Krenning; Erik de Blois; Marion de Jong; Antonius F W van der Steen
Journal:  J Nucl Cardiol       Date:  2020-02-05       Impact factor: 3.872

9.  The Effect of VPA Treatment on Radiolabeled DOTATATE Uptake: Differences Observed In Vitro and In Vivo.

Authors:  Maria J Klomp; Leo J Hofland; Lilian van den Brink; Peter M van Koetsveld; Fadime Dogan; Corrina M A de Ridder; Debra C Stuurman; Marian C Clahsen-van Groningen; Marion de Jong; Simone U Dalm
Journal:  Pharmaceutics       Date:  2022-01-12       Impact factor: 6.321
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.